Comparative Study of the Immunohistochemical Phenotype in Breast Cancer and Its Lymph Node Metastatic Location

Haba, Juan de la; Ruíz-Borrego, Manuel; España, A Gómez; Pastor, Carlos Villar; Japón, Miguel Á.; Travado, Paulino; Nogueira, J. A. Moreno; Rubio, F.; Aguilar, E. Aranda

doi:10.1081/cnv-120030210

Cited by 20 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tsutsui et al [13] found a high level of concordance in EGFR, c-erbB2 and p53 expression in primary tumors and matching metastatic axillary nodes. These results were not consistent with a study from De la Haba-Rodriguez et al [14], who found a concordant expression of ER, PgR, p53, HER-2 in primary tumors and metastatic lymph nodes in only about 40% of cases. In our study, although we report the paired expression in primary and matched node, we found lower levels of Bcl-2 and p53 expression (13 and 30%, respectively).…”

Section: Discussioncontrasting

confidence: 71%

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis

D’Andrea¹,

Limiti

Bari³

et al. 2006

Breast Cancer Res Treat

View full text Add to dashboard Cite

This study investigated the changes, if any, in the level of expression of a well defined panel of cell proliferation, differentiation and apoptosis markers between the primary breast tumor and the corresponding synchronous lymph node metastasis from a population of patients with a comparable disease status, in terms of clinical features, and natural history.Ninety pure invasive ductal carcinomas with 10 or more axillary lymph nodes involved and without evidence of distant metastasis were included in this study. Primary tumor and corresponding metastatic lymph node tissue specimens were evaluated for the expression of Cyclin B1, MMP1 metalloproteinase, ICAM-1, RARbeta, Ki67, ER, PgR, p53, bcl-2 and c-erbB2 by immunohistochemistry using standard methods. The bivariate Pearson correlation analysis demonstrated a close relationship between primary and matching corresponding metastatic node. A high grade of correlation has been maintained even when staining results where categorized as positive/negative according to each one marker cut-off level of staining expression. We report the most extensive immunohistochemical analysis of biological determinants in a well defined population of patients with invasive ductal carcinomas and involvement of 10 or more axillary nodes and no distant metastasis. We found a close correlation between the primary tumor and corresponding metastatic node in terms of the expression of all 10 of the markers investigated in this study. The not complete concordance observed could be explained by the gene expression modulation by extrinsic factors and by the microenvironment in which the cancer cells reside.

show abstract

Section: Discussioncontrasting

confidence: 71%

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis

D’Andrea¹,

Limiti

Bari³

et al. 2006

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…However, recent trials suggest hormone response rates can be as low as 30% [5,6]. Scant information is available regarding the correlation of primary hormone receptor status with metastatic hormone receptor status [7]. Most patients with ER or PR positive invasive breast cancers receive hormone treatment as part of adjuvant therapy [8].…”

Section: Introductionmentioning

confidence: 99%

Impact of metastatic estrogen receptor and progesterone receptor status on survival

Lower

Glass

Bradley

et al. 2005

Breast Cancer Res Treat

140

View full text Add to dashboard Cite

Hormone responsive breast cancer is usually determined by the presence of estrogen receptors (ER) or progesterone receptors (PR) on primary invasive breast cancers. Adjuvant and metastatic hormone therapy are recommended based on primary ER and PR determination. Little information is available to determine if primary hormone receptors correlate with metastatic disease and if survival is influenced by metastatic receptor status. We retrospectively compared primary to metastatic tumor ER and PR content from 200 metastatic breast cancer patients. ER and PR analyses were available in both primary and metastatic disease in 200 and 173 patients, respectively. There was a correlation between both the ER and PR in the primary and metastatic lesion (p < 0.001). However, in 60 of 200 (30%) patients, discordance between primary and metastatic ER was noted. Tumors from 68 of 173 (39.3%) showed discordance for PR. In 39 (19.5%) patients, the ER primary status was positive and metastatic status was negative and in 21 (10.5%) patients, the primary status was negative and metastatic status was positive. Survival from the time of metastatic diagnosis was calculated. Those patients with ER positive primary and metastatic tumors (Positive/Positive) or only the metastatic lesion (Negative/Positive) had similar median survival (1131 and 1111 days, respectively). However, patients with tumors that changed from positive primary to negative metastasis (Positive/Negative) experienced significantly shorter median survival (669 days, p < 0.05). Likewise, median survival (580 days) was significantly shorter for patients with primary and metastasis ER negative (Negative/Negative, p < 0.001) compared to Positive/Positive (p < 0.001) or compared to Negative/Positive (p < 0.02). The changes in PR status were not associated with a change in survival. We found a significant discordance between hormone receptor content of primary versus metastatic breast cancer. The ER status of the metastatic lesion was a better predictor of survival. Therefore, optimal metastatic treatment cannot be determined solely on primary ER and PR analysis.

show abstract

“…However, in our patient, the primary tumour lacked expression of oestrogen receptors. Modification of the expression of membrane proteins between primary and metastasis was studied by De la Haba-Rodriguez et al [4] in a series of 60 tumours. Sixty percent of the primary tumours presented a change in the expression of oestrogen and progesterone receptors, Ki-67 and HER-2 compared to the lymphatic metastasis.…”

Section: Discussionmentioning

confidence: 99%

Parotid gland metastasis of a breast cancer

et al. 2007

View full text Add to dashboard Cite

Parotid gland metastases from malignant tumors are extremely rare. A 61-year-old woman was diagnosed with an early breast cancer with no expression of oestrogen and progesterone receptors. Five years later the patient presented a tumour in parotid gland. After total parotidectomy, microscopic analysis of the gland demonstrated an invasive duct carcinoma (IDC) with positive expression of oestrogen receptor. The patient was treated with chemotherapy followed by complementary local radiotherapy. Diagnosis of a metastasic tumour in parotid gland poses a challenge. In our case an immunohistochemical study of oestrogen receptor was fundamental to establish a diagnosis.

show abstract

Comparative Study of the Immunohistochemical Phenotype in Breast Cancer and Its Lymph Node Metastatic Location

Cited by 20 publications

References 14 publications

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis

Impact of metastatic estrogen receptor and progesterone receptor status on survival

Parotid gland metastasis of a breast cancer

Contact Info

Product

Resources

About